FEATURED ARTICLE

What Is the Medicare GLP-1 Bridge Program and How Does It Work?

For 18 months beginning July 1, 2026, certain Medicare Part D enrollees can access select Medicare GLP-1 Bridge Program weight-management drugs for a flat $50 monthly cost. On the surface, it sounds straightforward. But the details matter, including who qualifies, what is excluded, and what this temporary program may tell us about the changing role of Medicare in weight management and preventive care.

Medicare GLP-1 Bridge Overview

The Centers for Medicare & Medicaid Services created the temporary Medicare GLP-1 Bridge Program, which runs from July 1, 2026 through December 31, 2027. The program gives certain Medicare Part D beneficiaries access to select GLP-1 medications for weight management for a flat $50 monthly cost.

The medications included in the program are Foundayo® (orforglipron), Wegovy® (semaglutide), and Zepbound® (tirzepatide). For Zepbound, only the KwikPen version is included. Other commonly discussed GLP-1 medications, including Ozempic and Mounjaro, are not included in the Bridge Program.

To participate, a beneficiary must meet the program’s eligibility requirements and receive prior authorization from a healthcare provider. Eligibility is not based on income or whether a Part D plan chooses to participate. Most standalone Part D plans and Medicare Advantage plans that include drug coverage qualify, but certain special plan types (such as private fee-for-service plans, cost contracts, or PACE organizations) generally do not.

One important detail is that the $50 monthly cost is separate from the standard Part D benefit. The amount paid through the Bridge Program does not count toward the beneficiary’s Part D deductible or annual out-of-pocket spending.

Medicare GLP-1 Bridge Program Eligibility

To qualify for the Medicare GLP-1 Bridge Program, you must have Medicare Part D, meet the program’s body mass index requirements, and not already be receiving a GLP-1 medication through your Part D coverage. Your prescribing healthcare provider must also submit a prior authorization request to the Medicare GLP-1 Bridge confirming that you meet the program’s eligibility requirements.

Certain Part D-coverable diagnoses can make you ineligible for the Bridge Program, including type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.

CMS currently provides three eligibility pathways for adults age 18 or older:

• BMI of 35 or higher

• BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension as defined by CMS, or chronic kidney disease stage 3a or higher

• BMI of 27 or higher plus prediabetes, a previous myocardial infarction, a previous stroke, or symptomatic peripheral artery disease

An important detail is that CMS uses your BMI at the time GLP-1 therapy was started, not necessarily your current BMI.

How do you apply for the Medicare GLP-1 Bridge Program?

You do not apply for the Medicare GLP-1 Bridge Program directly. The process starts with your healthcare provider and pharmacy.

First, your healthcare provider sends a prescription for an eligible GLP-1 medication to your pharmacy. The pharmacy then processes the prescription through the Medicare GLP-1 Bridge. This step has to happen before the prior authorization can be submitted. CMS specifically requires a pharmacy claim to be submitted to the Bridge before the prescribing provider sends the prior authorization request.

Once the pharmacy processes the claim and determines that prior authorization is needed, it will normally send a prior authorization request to your healthcare provider electronically or by fax. CMS says this typically happens within 24 to 72 hours.

Your healthcare provider then completes the Medicare GLP-1 Bridge Prior Authorization Request Form -attached. The form asks for information about you, your Medicare number, the medication being prescribed, your body mass index when GLP-1 therapy began, and certain medical conditions that determine whether you meet the program’s eligibility requirements. Your provider must also sign the form and certify that the information provided is accurate.

The provider submits the prior authorization directly to the Medicare GLP-1 Bridge. CMS allows providers to submit it electronically through CoverMyMeds or by fax at 1-800-530-2404. CMS encourages electronic submission when possible.

After the completed prior authorization is submitted, the Medicare GLP-1 Bridge reviews the request. CMS says an approval or denial is generally sent within 72 hours. The beneficiary receives the decision by mail, while the healthcare provider receives the decision electronically or by fax.

If approved, you can return to the pharmacy and receive the covered GLP-1 medication through the Bridge Program for the $50 monthly cost. The prior authorization remains valid through December 31, 2027, and subsequent fills generally do not require another prior authorization unless you switch from one covered GLP-1 drug to another.

The important point is that there is no separate application that you complete and send to Medicare yourself. Your role is to talk with your healthcare provider. Your provider and pharmacy handle the prescription, pharmacy claim, and prior authorization process required to determine whether you qualify.

How to Get Started With the Medicare GLP-1 Bridge Program

If you are interested in the Medicare GLP-1 Bridge Program, the best place to start is with your healthcare provider.

Ask whether you meet the program’s eligibility requirements and whether one of the covered GLP-1 medications may be appropriate for you. Your provider can review your medical history, body mass index, current medications, and any health conditions that could affect eligibility.

If your provider believes you qualify, they can send a prescription to your pharmacy. The pharmacy will process the prescription through the Medicare GLP-1 Bridge, and your provider can complete the required prior authorization if needed.

You may also want to confirm that your Medicare Part D coverage is active and make sure your pharmacy has your current Medicare information.

Because the Bridge Program is temporary and scheduled to run through December 31, 2027, it is also important to understand what may happen after the program ends and whether another source of coverage may be available at that time.

Key Takeaways

• The Medicare GLP-1 Bridge Program can significantly reduce the cost of certain weight-management medications for people who qualify.

• Eligibility is limited, so not every Medicare beneficiary who could benefit from a GLP-1 medication will have access through the program.

• The program is temporary, which means beneficiaries should also think about what their coverage and medication costs could look like after December 31, 2027.

• The Bridge Program raises broader questions about how Medicare should approach obesity treatment, long-term costs, access to care, and individual responsibility.

Fun Fact

Google DeepMind’s AlphaFold has predicted the 3D structures of more than 200 million proteins, essentially giving scientists a massive digital reference library for understanding how the building blocks of life are shaped. Pretty wild for something that started as an AI research problem

Have a blessed week!
Matt

Founder, Senior Healthcare Planning
Founder, Ashbury Boutique Wealth Management